Compare AMS & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMS | INAB |
|---|---|---|
| Founded | 1980 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 11.8M |
| IPO Year | 1995 | 2020 |
| Metric | AMS | INAB |
|---|---|---|
| Price | $1.08 | $0.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 8.1K | ★ 35.4K |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $19,714,000.00 | N/A |
| Revenue This Year | $16.37 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.81 | N/A |
| 52 Week Low | $1.14 | $0.80 |
| 52 Week High | $2.39 | $2.73 |
| Indicator | AMS | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 31.74 | 34.98 |
| Support Level | N/A | N/A |
| Resistance Level | $1.52 | $1.50 |
| Average True Range (ATR) | 0.06 | 0.08 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 42.86 | 2.00 |
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. Company operates in two segments, the medical equipment leasing segment where a contract exists between the hospital and the Company and the direct patient services segment, where a contract exists between the Company facilities and the individual treated at the facility. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates it's key revenue from the domestic market.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.